ArticleArthritis research & therapy2013
B cells tell scleroderma fibroblasts to produce collagen.
Article in Arthritis research & therapy, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 24 citations in OpenAlex.
- Belimumab for the Treatment of Early Diffuse Systemic Sclerosis: Results of a Randomized, Double-Blind, Placebo-Controlled, Pilot Trial.Arthritis & rheumatology (Hoboken, N.J.) · 2018Trial
- Safety and tolerability of an anti-CD19 monoclonal antibody, MEDI-551, in subjects with systemic sclerosis: a phase I, randomized, placebo-controlled, escalating single-dose study.Arthritis research & therapy · 2016Trial
- B cell depletion therapy upregulates Dkk-1 skin expression in patients with systemic sclerosis: association with enhanced resolution of skin fibrosis.Arthritis research & therapy · 2016Trial
- Mendelian randomization analysis of the causal relationship between immune cells and keloid.Dermatology reports · 2025Article
- The Microbiome in Systemic Sclerosis: Pathophysiology and Therapeutic Potential.International journal of molecular sciences · 2022Review
- B Cell Depletion Treatment in Resistant Systemic Sclerosis Interstitial Lung Disease.Mediterranean journal of rheumatology · 2022Review
- B cells in systemic sclerosis: from pathophysiology to treatment.Clinical rheumatology · 2021Review
- Targeting very early systemic sclerosis: a case-based review.Rheumatology international · 2019Review
- Treatment of systemic sclerosis associated fibrotic manifestations: Current options and future directions.Mediterranean journal of rheumatology · 2019Review
- Decreased CD22 expression and intracellular signaling aberrations in B cells of patients with systemic sclerosis.Rheumatology international · 2018Article
- Dkk1: A key molecule in joint remodelling and fibrosis.Mediterranean journal of rheumatology · 2017Review
- Diffuse parenchymal lung disease.European respiratory review : an official journal of the European Respiratory Society · 2017Review
- Proteoglycan expression correlates with the phenotype of malignant and non-malignant EBV-positive B-cell lines.Oncotarget · 2015Article
Corrections and comments
- Comment on
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In fibrosis fibroblasts are activated and overproduce collagen in a process with unknown drivers and equally unknown brakes that recently implicated a novel and surprising player, the B cell. B cells may be crucially involved in fibrosis in several ways: B cells may produce autoantibodies that can directly stimulate fibroblasts; B cells can produce profibrotic cytokines such as IL-6 or transforming growth factor beta; and, finally, B cells could directly stimulate fibroblasts by a contact-dependent mechanism. Recent experimental evidence suggests that B cells can enhance collagen production by fibroblasts, by a contact-dependent mechanism, and therefore are profibrotic ex vivo. These data strengthen the rationale of pursuing B-cell targeting therapies in systemic sclerosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.